301 related articles for article (PubMed ID: 27021607)
41. Update on belimumab for the management of systemic lupus erythematosus.
Lutalo PM; D'Cruz DP
Expert Opin Biol Ther; 2014 Nov; 14(11):1701-8. PubMed ID: 25303323
[TBL] [Abstract][Full Text] [Related]
42. An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.
Ramachandran S; Parks D; Kurtinecz M; Roth DA; Alfonso-Cristancho R
J Comp Eff Res; 2018 Jun; 7(6):581-593. PubMed ID: 29692179
[TBL] [Abstract][Full Text] [Related]
43. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.
Oon S; Huq M; Godfrey T; Nikpour M
Semin Arthritis Rheum; 2018 Oct; 48(2):221-239. PubMed ID: 29426575
[TBL] [Abstract][Full Text] [Related]
44. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.
Chatham W; Chadha A; Fettiplace J; Kleoudis C; Bass D; Roth D; Gordon D
Lupus; 2017 Dec; 26(14):1483-1490. PubMed ID: 28467293
[TBL] [Abstract][Full Text] [Related]
45. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
46. Belimumab: in systemic lupus erythematosus.
Burness CB; McCormack PL
Drugs; 2011 Dec; 71(18):2435-44. PubMed ID: 22141386
[TBL] [Abstract][Full Text] [Related]
47. Belimumab: A Review in Systemic Lupus Erythematosus.
Blair HA; Duggan ST
Drugs; 2018 Mar; 78(3):355-366. PubMed ID: 29396833
[TBL] [Abstract][Full Text] [Related]
48. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
49. Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice.
Pascoe K; Lobosco S; Bell D; Hoskin B; Chang DJ; Pobiner B; Ramachandran S
Clin Ther; 2017 Sep; 39(9):1811-1826. PubMed ID: 28803702
[TBL] [Abstract][Full Text] [Related]
50. Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis.
Shamliyan TA; Dospinescu P
Clin Ther; 2017 Jul; 39(7):1479-1506.e45. PubMed ID: 28673504
[TBL] [Abstract][Full Text] [Related]
51. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.
Wallace DJ; Atsumi T; Daniels M; Hammer A; Meizlik P; Quasny H; Schwarting A; Zhang F; Roth DA
Lupus; 2022 Nov; 31(13):1649-1659. PubMed ID: 36206400
[TBL] [Abstract][Full Text] [Related]
52. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
Strand V; Berry P; Lin X; Asukai Y; Punwaney R; Ramachandran S
Arthritis Care Res (Hoboken); 2019 Jun; 71(6):829-838. PubMed ID: 30320964
[TBL] [Abstract][Full Text] [Related]
53. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
Merrill JT; Ginzler EM; Wallace DJ; McKay JD; Lisse JR; Aranow C; Wellborne FR; Burnette M; Condemi J; Zhong ZJ; Pineda L; Klein J; Freimuth WW;
Arthritis Rheum; 2012 Oct; 64(10):3364-73. PubMed ID: 22674457
[TBL] [Abstract][Full Text] [Related]
54. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
Poh YJ; Baptista B; D'Cruz DP
Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
[TBL] [Abstract][Full Text] [Related]
55. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
Struemper H; Thapar M; Roth D
Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetic analysis of belimumab fails to identify robust genetic predictors of efficacy in lupus.
St Jean PL; Roth DA; McCarthy LC; Hughes AR
Pharmacogenet Genomics; 2019 Aug; 29(6):132-135. PubMed ID: 31058715
[TBL] [Abstract][Full Text] [Related]
57. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
J Rheumatol; 2015 Dec; 42(12):2288-95. PubMed ID: 26523030
[TBL] [Abstract][Full Text] [Related]
58. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
[TBL] [Abstract][Full Text] [Related]
59. Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.
Forbess LJ; Bresee C; Wallace DJ; Weisman MH
Lupus; 2017 Aug; 26(9):909-916. PubMed ID: 28173737
[TBL] [Abstract][Full Text] [Related]
60. 10 Years of belimumab experience: What have we learnt?
Levy RA; Gonzalez-Rivera T; Khamashta M; Fox NL; Jones-Leone A; Rubin B; Burriss SW; Gairy K; Maurik AV; Roth DA
Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]